DE69632734D1 - QUANTIFIZIERUNG VON p97 ZUR DIAGNOSE UND ÜBERWACHUNG DER ALZHEIMHER-KRANKHEIT - Google Patents

QUANTIFIZIERUNG VON p97 ZUR DIAGNOSE UND ÜBERWACHUNG DER ALZHEIMHER-KRANKHEIT

Info

Publication number
DE69632734D1
DE69632734D1 DE69632734T DE69632734T DE69632734D1 DE 69632734 D1 DE69632734 D1 DE 69632734D1 DE 69632734 T DE69632734 T DE 69632734T DE 69632734 T DE69632734 T DE 69632734T DE 69632734 D1 DE69632734 D1 DE 69632734D1
Authority
DE
Germany
Prior art keywords
diagnosis
disease
alzheimher
quantification
monitoring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69632734T
Other languages
English (en)
Other versions
DE69632734T2 (de
Inventor
A Jefferies
Malcolm Kennard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Application granted granted Critical
Publication of DE69632734D1 publication Critical patent/DE69632734D1/de
Publication of DE69632734T2 publication Critical patent/DE69632734T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
DE69632734T 1995-08-31 1996-08-30 QUANTIFIZIERUNG VON p97 ZUR DIAGNOSE UND ÜBERWACHUNG DER ALZHEIMHER-KRANKHEIT Expired - Lifetime DE69632734T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US520933 1990-05-09
US08/520,933 US5981194A (en) 1992-07-10 1995-08-31 Use of p97 and iron binding proteins as diagnostic and therapeutic agents
PCT/CA1996/000587 WO1997008560A1 (en) 1995-08-31 1996-08-30 QUANTITATION OF p97 TO DIAGNOSE AND MONITOR ALZHEIMER'S DISEASE

Publications (2)

Publication Number Publication Date
DE69632734D1 true DE69632734D1 (de) 2004-07-22
DE69632734T2 DE69632734T2 (de) 2005-06-30

Family

ID=24074638

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69632734T Expired - Lifetime DE69632734T2 (de) 1995-08-31 1996-08-30 QUANTIFIZIERUNG VON p97 ZUR DIAGNOSE UND ÜBERWACHUNG DER ALZHEIMHER-KRANKHEIT

Country Status (11)

Country Link
US (3) US5981194A (de)
EP (1) EP0847530B1 (de)
JP (1) JP3259963B2 (de)
CN (1) CN1198214A (de)
AT (1) ATE269545T1 (de)
AU (1) AU717198B2 (de)
CA (1) CA2230372C (de)
DE (1) DE69632734T2 (de)
IL (1) IL123441A (de)
NZ (1) NZ315997A (de)
WO (1) WO1997008560A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905817B1 (en) * 1998-10-01 2005-06-14 Licestia Ltd. Ret-independent signaling pathway for GDNF
JP4414023B2 (ja) * 1999-08-05 2010-02-10 オリエンタル酵母工業株式会社 関節炎関連メラノトランスフェリンの測定方法および試薬
US6586239B1 (en) * 2000-01-07 2003-07-01 Agy Therapeutics, Inc. Purifying microglial cells by binding cell Fc receptor to immunoglobulin G Fc domain
EP1285272A2 (de) * 2000-02-08 2003-02-26 University of British Columbia Zusammensetzungen und verfahren zum screenen von therapeutischen agenzien
US7640062B2 (en) 2000-05-08 2009-12-29 Brainsgate Ltd. Methods and systems for management of alzheimer's disease
JP2004534511A (ja) * 2000-11-27 2004-11-18 プラエシス ファーマシューティカルズ インク． アミロイド形成性疾患を治療するための治療薬及びその使用法
US7560424B2 (en) * 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
JP4641705B2 (ja) * 2001-04-30 2011-03-02 ザイストール セラピューティクス， インコーポレイテッド 治療的タンパク質の亜細胞標的化
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
CA2450073C (en) * 2001-07-25 2017-08-29 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US8129504B2 (en) * 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US20050158296A1 (en) * 2002-01-11 2005-07-21 Starr Christopher M. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
US7684859B2 (en) 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
EP1534823A4 (de) * 2002-07-12 2008-12-31 Biomarin Pharm Inc Verwendung von isocyanatlinkern zur herstellung von hydrolysierbaren wirkstoff-biopolymer-konjugaten
CA2498345A1 (en) * 2002-10-18 2004-04-29 Promega Corporation Methods for separating molecules
EP1585430B1 (de) 2002-11-14 2017-01-11 Brainsgate Ltd. Chirurgische instrumente und verfahren zur stimulation
US7919103B2 (en) * 2003-05-09 2011-04-05 Transfert Plus Compound and method for regulating plasminogen activation and cell migration
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
JP4914224B2 (ja) * 2004-02-10 2012-04-11 バイオマリン ファーマシューティカル インコーポレイテッド 酸性αグルコシダーゼおよびそのフラグメント
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
WO2005087801A1 (en) * 2004-03-05 2005-09-22 The Board Of Trustees Of The University Of Illinois Peptide carrier for drug delivery
CA2669347A1 (en) * 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Methods for treating pompe disease
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
WO2009120168A1 (en) * 2008-03-28 2009-10-01 Chyna Llc Use of ferritin to treat iron deficiency disorders
EP3778652A1 (de) * 2008-05-07 2021-02-17 BioMarin Pharmaceutical Inc. Auf lysosomen gerichtete peptide und verwendungen davon
EP3075386B1 (de) 2009-06-17 2019-10-16 BioMarin Pharmaceutical Inc. Formulierungen für lysosomale enzyme
US9150846B2 (en) 2011-07-05 2015-10-06 Bioasis Technologies, Inc. P97-antibody conjugates and methods of use
WO2013022738A1 (en) 2011-08-05 2013-02-14 Bioasis Technologies, Inc. P97 fragments with transfer activity
EP2880156B1 (de) 2012-07-31 2017-08-23 biOasis Technologies Inc Dephosphorylierte proteine lysosomaler speicherkrankheiten und verwendung davon
ES2774549T3 (es) 2013-03-13 2020-07-21 Bioasis Technologies Inc Fragmentos de P97 y usos de los mismos
EP2878335B1 (de) 2013-11-10 2018-01-03 Brainsgate Ltd. Implantat und implantationssystem für nervenstimulator
AU2015210612B2 (en) 2014-02-03 2020-04-09 Bioasis Technologies Inc. P97 fusion proteins
WO2015126729A1 (en) 2014-02-19 2015-08-27 Bioasis Technologies, Inc. P97-ids fusion proteins
US10058619B2 (en) 2014-05-01 2018-08-28 Bioasis Technologies, Inc. P97-polynucleotide conjugates
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
EP3093043B1 (de) 2015-05-13 2018-11-14 Brainsgate Ltd. Implantat und abgabesystem für nervenstimulator
US11752315B1 (en) 2016-10-07 2023-09-12 Carlos A. Hakim Method of treating normal pressure hydrocephalus
US10473672B2 (en) * 2017-02-09 2019-11-12 Kaohsiung Chang Gung Memorial Hospital Methods for diagnosing and treating Alzheimers disease using G72 protein and SLC7A11 mRNA as biomarkers
CN113430146B (zh) * 2021-07-28 2023-03-17 西安医学院 表达石杉碱甲的苏云金芽孢杆菌hw1株及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
GB2116979B (en) * 1982-02-25 1985-05-15 Ward Page Faulk Conjugates of proteins with anti-tumour agents
US4522750A (en) * 1984-02-21 1985-06-11 Eli Lilly And Company Cytotoxic compositions of transferrin coupled to vinca alkaloids
GB2188637B (en) * 1986-02-07 1990-11-14 Oncogen Vaccines against melanoma
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4902505A (en) * 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5034223A (en) * 1986-10-09 1991-07-23 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US5182107A (en) 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5672683A (en) 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5154924A (en) 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
AU4553793A (en) * 1992-07-10 1994-01-31 University Of British Columbia, The Use of p97 and iron binding proteins as diagnostic and therapeutic agents

Also Published As

Publication number Publication date
AU717198B2 (en) 2000-03-23
CN1198214A (zh) 1998-11-04
IL123441A0 (en) 1998-09-24
JP3259963B2 (ja) 2002-02-25
WO1997008560A1 (en) 1997-03-06
IL123441A (en) 2001-01-11
US5981194A (en) 1999-11-09
JPH11511257A (ja) 1999-09-28
EP0847530B1 (de) 2004-06-16
AU6783496A (en) 1997-03-19
US6455494B1 (en) 2002-09-24
CA2230372C (en) 2008-04-29
US20030077693A1 (en) 2003-04-24
DE69632734T2 (de) 2005-06-30
EP0847530A1 (de) 1998-06-17
CA2230372A1 (en) 1997-03-06
ATE269545T1 (de) 2004-07-15
NZ315997A (en) 1999-08-30

Similar Documents

Publication Publication Date Title
DE69632734D1 (de) QUANTIFIZIERUNG VON p97 ZUR DIAGNOSE UND ÜBERWACHUNG DER ALZHEIMHER-KRANKHEIT
CA2139862A1 (en) Use of p97 and iron binding proteins as diagnostic and therapeutic agents
ATE445838T1 (de) Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
ATE459335T1 (de) Verfahren zur behandlung von augenerkrankungen
FI972287A (fi) Uudenlaisia polysubstituoituja DTPA-johdoksia ja niiden metallikomplekseja, kyseisiä komplekseja sisältäviä farmaseuttisia aineita, niiden käyttö diagnosoinnissa ja terapiassa sekä menetelmiä kyseisten kompleksinmuodostajien ja kompleksien valmistamiseksi ja menetelmiä kyseisten.
ATE209918T1 (de) Transdermales estradiol/progestogen-pflaster und dessen herstellung
WO1998027227A3 (en) Pharmacogenetic methods for use in the treatment of nervous system diseases
CY1112845T1 (el) Παραγωγα της 1-δεοξυ-γαλακτονογιριμυκινης και η χρηση τους στη θεραπεια αθροιστικων λυσοσωμικων ασθενειων μεσω ενισχυσης της λυσοσωμικης α-γαλακτοσιδασης α
EP1007048A4 (de) Identifizierung von mitteln zur behandlung der alzheimerischen krankheit
CY1109151T1 (el) Αντισωματα dr4 και χρησεις αυτων
ZA978557B (en) Process for the determination of APP secretase modulators and the use thereof as agents in the treatment of a Alzheimer's disease.
IL141507A0 (en) Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas
PL338673A1 (en) Application of fanquinone in treating alzheimer disease
EP0513000A4 (de) Qualitätssteigerung von mr-bildern von knochen und ähnlichem gewebe mittels paramagnetischer kationenkomplexe und polyphosphonatliganden.
YU121380A (en) Process for obtaining 11-alkylene morphanetidrine
BG104801A (en) Indole-2,3-dione-3-oxime derivatives for therapeutical use
DK0478631T3 (da) Målsøgende midler
AU2907700A (en) Use of desoxypeganine in the treatment of alzheimer's dementia
EP0396080A3 (de) Serinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung in der Humantherapie
DE19680940D2 (de) Vorrichtung zum Bestimmen der Form eines Pferderückens
ATA57894A (de) Mittel zur behandlung von osteoporose
Dorazil et al. Examination of the Hardenability of Ductile Cast Iron in Austempering
DE29719570U1 (de) Vorrichtung zum Bestimmen der Form eines Pferderückens
ZA9510198B (en) Novel, multiply, substituted dtpa derivatives and their metal complexes, pharmaceutical agents that contain these complexes, their use in diagnosis and therapy, as well as process for the production of pharmaceutical agents
FI890954A0 (fi) Anordning foer begraensning av den magnetiska straolningen i katodstraoleroermonitorer.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition